ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2223

Monitoring Of Active Matrix Metalloproteinase-3 Using

Sung Jae Choi1, Young Ho Seo2, Young Ho Lee3, Jong Dae Ji1, Gwan Gyu Song4, Aeju Lee2 and Jae-Hoon Kim4, 1Rheumatology, Korea University Medical Center, Seoul, South Korea, 2Rheumatology, Korea University Medical center, Seoul, South Korea, 3Internal Medicine, Rheumatology, Korea University Medical Center, Seoul, South Korea, 4Div of Rheum, Dept of Int Med, Korea Univ College of Med, Seoul, South Korea

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Animal models, infliximab, matrix metalloproteinase (MMP), methotrexate (MTX) and rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Animal Models II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Active matrix metalloproteinase-3 (MMP-3) is a prognostic marker of rheumatoid arthritis (RA). Recently, we developed the MMP-3 probe which can specifically detect an active MMP-3.

Methods:

The aim of this study was to investigate whether detecting and monitoring of active MMP-3 using the MMP-3 probe will be useful to predict therapeutic drug responses in collagen-induced arthritis (CIA) mice. During the period of drug treatments such as methotrexate (MTX) or infliximab (IFX), fluorescence signals in arthritic joint tissues and in serum of CIA mice were monitored using the MMP-3 probe to correlate with MMP-3 mRNA and protein levels. Also, micro-computed tomography (micro-CT), X-ray and histology were performed to confirm drug responses.

Results:

Strong fluorescence signals observed in joint tissues and serum of CIA mice were significantly decreased when drugs were treated (Fig. 1.). The decrease of RA scores in drug-treated CIA mice leads to the fluorescence reductions, which is mainly due to down-regulation of MMP-3 mRNA or protein levels. The results that micro-CT, X-ray (Fig. 2.) and histology clearly showed the markedly decrease of bone and cartilage destruction were consistent with the fluorescence reduction by down-regulation of active MMP-3 in drug-treated CIA mice.

Conclusion:

We suggested that the MMP-3 probe could detect and monitor active MMP-3 of CIA mice serum in treatment course, and thereby predicting the drug response or resistance to RA therapies at an earlier stage. We hope that the MMP-3 probe will be a promising tool for drug discovery, development and drug responses in RA therapy.

Figure 1. In vivo monitoring of RA activities and active MMP-3 levels using “smart probe” in arthritic joints of CIA mice with or without MTX or IFX treatment.

Figure 2. Three-dimensional reconstructions of micro-CT images and bone volume analysis using micro-CT in the knee joints and the paws of normal (n=5), CIA (n=5), and MTX (n=5) or IFX (n=5)-treated CIA mice at 3, 5, and 7 weeks after the first immunization.


Disclosure:

S. J. Choi,
None;

Y. H. Seo,
None;

Y. H. Lee,
None;

J. D. Ji,
None;

G. G. Song,
None;

A. Lee,
None;

J. H. Kim,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/monitoring-of-active-matrix-metalloproteinase-3-using/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology